<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528069</url>
  </required_header>
  <id_info>
    <org_study_id>ILX140-P001</org_study_id>
    <nct_id>NCT04528069</nct_id>
  </id_info>
  <brief_title>Clinical Investigation of the Visual Outcomes and Safety of a Trifocal Toric IOL in an Asian Population</brief_title>
  <official_title>Clinical Investigation of the Visual Outcomes and Safety of AcrySof® IQ PanOptix® Toric Trifocal IOLs in an Asian Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical performance of the ACRYSOF® IQ&#xD;
      PanOptix® Toric Trifocal intraocular lens (IOL) when implanted in the eye following cataract&#xD;
      removal in an Asian population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both eyes will be implanted with the PanOptix Toric Trifocal IOL. The eye with the highest&#xD;
      astigmatism will be implanted first. The second eye will be implanted within 7-14 days of the&#xD;
      first eye.&#xD;
&#xD;
      Subjects will attend 10 scheduled visits as follows: 1 screening visit, 1 operative visit and&#xD;
      2 post-operative visits for each eye, and 3 postoperative visits where both eyes will be&#xD;
      evaluated.&#xD;
&#xD;
      This study will be conducted in Australia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean monocular residual manifest cylinder</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>Mean monocular residual manifest cylinder will be calculated for all IOL models combined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of IOLs with less than 10 degree rotation</measure>
    <time_frame>Day 1 postoperative, up to Month 6</time_frame>
    <description>Rotation is defined as the difference in IOL axis of orientation from Day 1 postoperative</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean binocular Best Corrected Distance Visual Acuity (BCDVA)</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>Visual acuity will be assessed at a distance of 4 meters under well-lit conditions with spectacles or other visual corrective devices in place. Eyes will be assessed together.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean binocular Distance Corrected Intermediate Visual Acuity (DCIVA)</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>Visual acuity will be assessed at a distance of 60 centimeters under well-lit conditions with spectacles or other visual corrective devices in place. Eyes will be assessed together.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean binocular Distance Corrected Near Visual Acuity (DCNVA)</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>Visual acuity will be assessed at a distance of 40 centimeters under well-lit conditions with spectacles or other visual corrective devices in place. Eyes will be assessed together.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Secondary Surgical Interventions (SSIs), by category</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>A secondary surgical intervention (SSI) is defined as a surgical procedure occurring after primary implantation of the IOL. The rate of SSIs will be reported categorically, as the rate of SSIs related to optical properties of the IOL, and the rate of all SSIs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of visual disturbances, by category</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>Visual disturbances will be assessed by the subject using the Questionnaire for Visual Disturbances (QUVID) and reported categorically as &quot;severe&quot; and &quot;most bothersome.&quot; This outcome measure is pre-specified for subjects with binocular implantation (both eyes).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>An adverse event (AE) is defined as untoward medical occurrence, unintended disease or injury, or untoward clinical sign (including abnormal laboratory findings) in subjects, users, or other persons, whether or not related to the investigational medical device (test product).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Aphakia</condition>
  <condition>Corneal Astigmatism</condition>
  <arm_group>
    <arm_group_label>PanOptix Toric Trifocal IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PanOptix Toric Trifocal IOL implanted in the capsular bag in the posterior chamber following cataract surgery and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACRYSOF® IQ PanOptix® Toric Trifocal IOL</intervention_name>
    <description>Single-piece, ultraviolet and blue-light filtering, foldable, multifocal toric IOL intended to provide vision to aphakic subjects at near, intermediate, and distance and to correct pre-existing corneal astigmatism. This device is approved in Australia.</description>
    <arm_group_label>PanOptix Toric Trifocal IOL</arm_group_label>
    <other_name>PanOptix Toric Trifocal IOL</other_name>
    <other_name>Models TFNT30, TFNT40, TFNT50, TFNT60</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cataract surgery</intervention_name>
    <description>Cataract extraction by phacoemulsification, followed by implantation of the IOL per investigator's standard of care and instructions for use</description>
    <arm_group_label>PanOptix Toric Trifocal IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Planned bilateral cataract removal followed by posterior chamber IOL implantation with&#xD;
             PanOptix Toric (TFNT30, TFNT40, TFNT50, or TFNT60);&#xD;
&#xD;
          -  Calculated target residual refractive error within ±0.50 diopter (D) of emmetropia&#xD;
             within the commercially available IOL Power Range in both operative eyes;&#xD;
&#xD;
          -  Preoperative regular corneal keratometric astigmatism with predicted residual&#xD;
             refractive astigmatism ≤ 0.50 diopter (D) in both operative eyes;&#xD;
&#xD;
          -  Other protocol-defined inclusion criteria may apply.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Preoperative irregular astigmatism;&#xD;
&#xD;
          -  Clinically significant corneal abnormalities;&#xD;
&#xD;
          -  Glaucoma;&#xD;
&#xD;
          -  History of or current retinal disease; anterior or posterior segment inflammation;&#xD;
&#xD;
          -  Other planned ocular surgical procedures including, but not limited to, limbal&#xD;
             relaxing incision (LRI);&#xD;
&#xD;
          -  Other protocol-defined exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sr. Clinical Trial Lead, CDMA Surgical</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Campsie</city>
        <state>New South Wales</state>
        <zip>2194</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intraocular lens</keyword>
  <keyword>Cataract</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
    <mesh_term>Aphakia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

